Stereoselective cardiotoxic effects of terodiline

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 1, 1996, Pages 89-98

  Hartigan Go, Kenneth ^a,c   Bateman, D Nicholas ^a   Daly, Ann K ^a   Thomas, Simon H L ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Wolfson U of Clinical Pharmacology   (United Kingdom)

^c UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TERODILINE;

ADULT; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; ELECTROCARDIOGRAM; ENANTIOMER; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; STEREOSPECIFICITY;

EID: 0029776056     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90171-X     Document Type: Article

References (21)

1. Noronha-Blob L. Prosser JC, Sturm BL, Lowe VC, Enna SJ. (±)-Terodiline, an Mi-selective muscarinic receptor antagonist: in vivo effects at muscarinic receptors mediating urinary bladder contraction, mydriasis and salivary secretion. Eur J Pharmacol 1991;201: 135-42.
2. Larsson-Backström C, Arrenius E, Sagge K. Comparison of the calcium-antagonistic effects of terodiline, nifedipine and verapamil. Acta Pharmacol Toxicol 1985;57:8-17.
3. Kura H, Yoshino M, Yabu H. Blocking action of terodiline on calcium channels in single smooth muscle cells of the guinea pig bladder. J Pharm Exp Ther 1992;261:724-9.
4. McCloud AA, Thorogood S, Barnett S. Torsade de pointes complicating treatment with terodiline. Br Med J 1991;302:1469.
5. Connolly MJ, Astrige PS, White EG, Morley CA, Campbell Cowan J. Torsade de pointes ventricular tachycardia and terodiline. Lancet 1991;338:344-5.
6. Stewart DA, Taylor J, Ghosh S, McPhee GJA, Abdullah JM, McLenachan JM, et al. Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur J Clin Pharmacol 1992;42:577-80.
7. Thomas SHL, Higham PD, Hartigan-Go K, Kamali F, Wood P, Campbell RWF, et al. Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence. Br Heart J 1995;74:53-6.
8. Thomas SHL. Drugs, QT interval prolongation and ventricular arrhythmias. Adverse Drug React Toxicol Rev 1994;13:77-102.
9. Hu JTY, Wyse DG, Gillis AM, Duff HJ, Solyo MA, Mitchell LB. Precordial QT interval dispersion as a marker of torsade de pointes: disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 1992;86:1376-82.
10. Day CP, McComb JM, Campbell RWF. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990;63:342-4.
11. Hallén B, Gabrielsson J, Palmer L, Ekström B. Pharmacokinetics of R(+)-terodiline given intravenously and orally to healthy volunteers. Pharmacol Toxicol 1993;73:153-8.
12. Hallén B, Karlsson MO, Stromberg S, Noren B. Bioavailability and disposition of terodiline in man. J Pharm Sci 1994;83:1241-6.
13. Norén B, Stromberg S, Ericsson Ö, Lindeke B. Biotransformation of terodiline; IV: identification of unconjugated and conjugated metabolites in dog and human urine. Acta Pharm Suecica 1988;25:281-92.
14. Karlén B, Andersson KE, Ekman G, Ulmsten U. Pharmacokinetics of terodiline in human volunteers. Eur J Clin Pharmacol 1982;23:267-70.
15. Hallén B, Magnusson A, Bogentoft S, Ekelund P. Single- and multiple-dose pharmacokinetics of terodiline in geriatric patients. Eur J Clin Pharmacol 1988; 34:291-7.
16. Andersson KE, Ekström B, Mattiasson A. Actions of terodiline, its isomers and main metabolite on isolated detrusor muscle from rabbit and man. Acta Pharmacol Toxicol 1988;63:390-5.
17. Dollery CT, Davies DS, Draffan GH, Dargie HJ, Dean CR, Reid JL, et al. Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther 1976;19:11-7.
18. Wood P, Thomas SHL, Kamali F. Measurement of the (R)- and (S)-enantiomers of terodiline in human plasma by chiral high performance liquid chromatography. Br J Clin Pharmacol 1995;39:558P-9P.
19. Daly AK, Armstrong M, Monkman SG, Idle ME, Idle JR. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1991;1:33-41.
20. Daly AK, Steen VM, Fairbrother KS, Idle JR. CYP2D6 multiallelism. Methods Enzymol [in press].
21. Norén B, Stromberg S, Ericsson O, Lindeke B. Biotransformation of terodiline: stereoselectivity in hydroxylation by human liver microsomes. Chem Biol Interact 1989;71:325-37.